TL;DR
Get business pricing on office and shipping supplies
- Business-only prices and quantity discounts
- Tax-exempt purchasing
- Multiple users, one account, clear invoices
Sobi’s Nomination Committee has proposed Börje Ekholm for election as a board member and chair at the company’s 2027 Annual General Meeting. Current chair David Meek will remain in the role until May 2027 and has decided not to stand for re-election.
Sobi’s Nomination Committee has proposed Börje Ekholm for election as a board member and chair at the Swedish biopharmaceutical company’s 2027 Annual General Meeting, after current chair David Meek decided not to seek re-election. Meek is expected to continue as chair until the end of his term in May 2027; Ekholm’s appointment is not yet final and requires shareholder approval at the AGM.
The committee announced its proposal on October 29, 2026. It said Ekholm brings more than 30 years of experience in technology, investment management and international business leadership. He recently stepped down as chief executive of Ericsson and previously led Patricia Industries and Investor AB. He currently chairs Trimble Inc. and is due to join Nasdaq Inc.’s board on November 1, 2026, according to Sobi’s announcement.
Ekholm has also held board roles at Alibaba, Husqvarna, Nasdaq, Scania and WM Data, and serves as a board adviser to Mars Inc. and an adviser to Ericsson’s chief executive. Sobi said he is familiar with the company: during his time as Investor AB chief executive, he was involved in the creation of Sobi through the merger of Biovitrum and Swedish Orphan International, working with the company from an owner’s perspective.
Meek has chaired Sobi’s board since December 2024. The company said that during his tenure it recorded growth and shareholder returns, expanded access to medicines through launches and indication extensions, and strengthened its clinical development pipeline. Those assessments are Sobi’s characterization of the period; the announcement did not provide figures or a breakdown of the results.
A Leadership Change at Sobi
The proposal puts a potential change in board leadership before Sobi shareholders while the company continues to pursue growth in rare-disease medicines. A board chair helps guide the board’s work and oversight, but the role is distinct from running day-to-day operations. The announcement concerns governance, not a change to Sobi’s leadership team, products or strategy.
Ekholm’s experience across corporate leadership and boards, alongside his prior involvement with Sobi’s formation, is the committee’s stated rationale for nominating him. If shareholders elect him, that combination could inform board oversight as Sobi develops its pipeline and expands the reach of its medicines. The company has not announced any specific policy or business changes tied to the proposed appointment.
Popular right now
Ninja Specialty Coffee Maker CM401, 10-Cup Carafe, Fold-Away Frother, Black
eufy E25 Robot Vacuum and Mop Combo with HydroJet Roller Mop
Dyson V8 Cyclone Cordless Vacuum
As an affiliate, we earn on qualifying purchases.
From Meek’s Tenure to the 2027 Vote
The change is planned through Sobi’s annual shareholder-governance process rather than an immediate departure. Meek told the Nomination Committee he would not stand for another term. He remains chair for the rest of his current term, with the expected handover dependent on the 2027 AGM and the outcome of the vote.
Sobi, formally Swedish Orphan Biovitrum AB, is a Stockholm-listed biopharmaceutical company focused on rare diseases. The company reported 2025 revenue of SEK 28 billion and said it has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. These details provide company context; they do not indicate that the proposed chair appointment will change financial performance or operations.
Ekholm has been proposed, not elected. Shareholders will decide at Sobi’s 2027 AGM whether to elect him as both a board member and chair. The announcement does not give the AGM date or publish the committee’s full slate of nominations; Sobi said those details would be released in due time before the meeting.
The company has not outlined any changes to strategy or board priorities that would follow an election. It also did not provide detailed performance measures supporting its description of growth and shareholder returns during Meek’s tenure. Those matters remain separate from the confirmed facts of his planned departure and the committee’s recommendation.
Sobi’s 2027 AGM Decision
Sobi’s Nomination Committee is expected to publish its complete proposals ahead of the 2027 AGM. Shareholders will then vote on Ekholm’s proposed election as a board member and chair. Until the end of Meek’s term in May 2027, he is set to remain in the chair position; the precise handover timing will depend on the AGM decision and the company’s subsequent arrangements.
Key Questions
Has Börje Ekholm been appointed Sobi’s chair?
No. Sobi’s Nomination Committee has proposed him for election as a board member and chair. Shareholders must vote on the proposal at the 2027 AGM.
When will David Meek leave the chair position?
Meek will continue as chair for the remainder of his current term, which Sobi says runs until May 2027. He has decided not to stand for re-election.
Why did the committee propose Ekholm?
The committee cited his more than 30 years of experience in technology, investment management and international business leadership, along with his familiarity with Sobi and involvement in the company’s creation.
When will shareholders vote on the proposal?
The vote is expected at Sobi’s 2027 Annual General Meeting. The company has not yet announced the meeting date and says the complete nomination proposals will be published in due time before the AGM.
Source: prnewswire.com
